Cefpirome

證據等級: L5

預測適應症: 10 個

Cefpirome: From Bacterial Infections to Rheumatoid Arthritis

One-Sentence Summary

Cefpirome is a fourth-generation cephalosporin antibiotic developed to treat serious bacterial infections caused by both gram-positive and gram-negative organisms, including those resistant to earlier-generation cephalosporins. The TxGNN model predicts it may be effective for Rheumatoid Arthritis (score: 98.31%), however there are currently 0 clinical trials and 0 publications supporting this direction — making this a purely model-driven hypothesis.

Quick Overview

Item	Content
Original Indication	Fourth-generation cephalosporin antibiotic for serious bacterial infections (no India-registered indication on record)
Predicted New Indication	Rheumatoid Arthritis
TxGNN Prediction Score	98.31%
Evidence Level	L5
India Market Status	✗ Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on known pharmacological class, Cefpirome is a fourth-generation cephalosporin that exerts its antibacterial effect by binding to penicillin-binding proteins (PBPs) on bacterial cell walls, inhibiting cell wall synthesis. Its fourth-generation classification confers broad-spectrum activity and resistance to many beta-lactamases.

The mechanistic bridge to rheumatoid arthritis is speculative but not entirely without precedent. Some cephalosporins — notably cefoperazone — have demonstrated anti-inflammatory properties in preclinical settings, including inhibition of matrix metalloproteinases (MMPs) such as MMP-1, MMP-3, and MMP-13, which are key enzymes driving joint destruction in RA. TxGNN may be drawing an inference through PBP-adjacent protein nodes that share structural homology with arthritis-related targets in the knowledge graph.

A second proposed pathway involves the gut microbiome: antibiotic exposure alters intestinal microbial composition, and dysbiosis has been increasingly linked to immune dysregulation relevant to RA pathogenesis. However, this connection is indirect, highly context-dependent, and remains entirely speculative for Cefpirome specifically. No published preclinical or clinical data supports Cefpirome as an anti-arthritic agent. The TxGNN signal here most plausibly reflects shared graph neighbourhood rather than a validated pharmacological relationship.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Cefpirome has no registered drug licenses in India. The drug is not currently marketed and has no approved indications on record with CDSCO.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: All ten predicted indications for Cefpirome sit at Evidence Level L5 — the lowest tier — with zero supporting clinical trials or published literature across any of the predicted diseases. The top prediction (rheumatoid arthritis, 98.31%) appears to reflect indirect knowledge graph pathways rather than a validated pharmacological connection. Crucially, Cefpirome itself has no approved indication or market presence in India, and foundational safety data (package insert warnings, contraindications) is unavailable for review.

To proceed, the following is needed:

MOA confirmation: Retrieve Cefpirome’s full mechanism of action from DrugBank API (DB13682) to evaluate whether any known targets overlap with RA or musculoskeletal disease pathways
Safety dossier: Download and parse the originating regulatory package insert (EMA or CDSCO equivalent) to establish key warnings and contraindications before any repurposing evaluation can advance to Stage 1
Preclinical evidence search: Conduct a broader literature search using MeSH terms combining cephalosporins + inflammation + MMP + rheumatoid to determine if any class-level evidence exists that could support a Cefpirome hypothesis
KG artifact review: Evaluate whether the clustering of musculoskeletal predictions (ranks 1–5: RA, osteoarthritis, osteoarthritis susceptibility, gout, pseudoachondroplasia) represents a genuine signal or systematic false positives due to shared ECM/cartilage protein nodes in the TxGNN knowledge graph
India market pathway: If evidence eventually supports advancement, a full CDSCO new drug application pathway would be required given zero existing market presence

⚠️ Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.